Research Equity is the Foundation of Health Equity
Race, ethnicity, age, sex, environment, and other social determinants of health can all impact how different people respond to the same medicine or vaccine. This is why diversity and inclusivity at every stage of the medical research process are critical to learning about the safety and efficacy of potential treatments for all patients. Presented by Pfizer.
Health Fellow Spotlight: Lea Masamo, Africa Sickle Cell Organisation
Meet Lea Masamo, a 2022 Aspen Ideas: Health Fellow who's building a movement of people living with sickle cell disease to advocate for programs and policies needed to improve access to quality health care.
Searching the World Around Us for Clues About Our Health
Can the data collected through smartphones, wearable sensors, and passive monitoring devices be turned into actionable knowledge about the environmental impacts on our health? Meet three innovative researchers who are using these technologies to unlock the mysteries of Crohn’s disease and more. Presented by the Helmsley Charitable Trust.
Building the Case for Greater Investment in Health
Did you know that only 7% of the investments made within the $715 billion global impact investing market go toward health? Learn how Johnson & Johnson Impact Ventures is leading the way on smart investments in inclusive innovation at the front lines of care to help improve the lives of billions of people around the world.
Broader Access is Vital to the Future of Testing and Healthcare Innovation
Building on lessons learned from the COVID-19 pandemic, there are significant opportunities to expand the use of rapid testing to address many health challenges around the world- from infectious diseases like malaria and HIV to non-infectious health needs like prenatal care. Learn how Abbott is intentionally approaching product development to democratize, decentralize and...
Faced with the COVID-19 pandemic, the healthcare industry had to quickly adapt to confront the rapidly evolving challenges facing its patients, customers, and employees. Learn how three key decisions enabled Merck & Co. to accelerate innovation in 2020 and why these lessons will be critical to future success in addressing the most pressing healthcare challenges.
Ronald Klain was White House Ebola Response Coordinator from 2014 to 2015. This post has been updated and adopted from the author’s piece, Confronting the Pandemic Threat, published in Democracy Journal (No. 40, Spring 2016).